Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

BioAge Labs (BIOA) Accounts Payables (2023 - 2026)

BioAge Labs' Accounts Payables history spans 3 years, with the latest figure at $2.7 million for Q4 2025.

  • On a quarterly basis, Accounts Payables rose 33.97% to $2.7 million in Q4 2025 year-over-year; TTM through Dec 2025 was $2.7 million, a 33.97% increase, with the full-year FY2025 number at $2.7 million, up 33.97% from a year prior.
  • Accounts Payables hit $2.7 million in Q4 2025 for BioAge Labs, down from $5.0 million in the prior quarter.
  • Over the last five years, Accounts Payables for BIOA hit a ceiling of $5.0 million in Q3 2025 and a floor of $1.3 million in Q2 2025.
  • Historically, Accounts Payables has averaged $2.7 million across 3 years, with a median of $2.1 million in 2024.
  • Biggest five-year swings in Accounts Payables: rose 6.97% in 2024 and later soared 139.18% in 2025.
  • Tracing BIOA's Accounts Payables over 3 years: stood at $1.9 million in 2023, then rose by 6.97% to $2.0 million in 2024, then skyrocketed by 33.97% to $2.7 million in 2025.
  • Business Quant data shows Accounts Payables for BIOA at $2.7 million in Q4 2025, $5.0 million in Q3 2025, and $1.3 million in Q2 2025.